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ABSTRACT
Bovine corneal endothelial cells (BCECs) have been shown in our lab to
synthesize and secrete endothelin-1 (ET-1). The endothelin-1 binds ETA receptors, this
elevates intracellular calcium, stimulate DNA replication and cell division. This
investigation explores ET-l's role as a mitogenic factor in corneal endothelial cells and
addresses whether mitogenic activity is mediated through the cyclin dependent kinase
inhibitor p27. BCEC were isolated from bovine eyes and grown in DMEM-10% serum
in a 5% C0 2 , 37° C incubator. Confluent cultures of BCEC were incubated for 24 hours
with lOOnM Endothelin-1, luM BQ123 and BQ123 +100nM Endothelin-1 and some left
untreated. Total cellular protein was isolated and the concentration quantified by the
Peterson modification of the Lowry protein assay. Protein samples and prestained
molecular weight standards were separated by 4-15% gradient SDS-PAGE and
transferred overnight to PVDF Hyperbond membrane by western blot. The relative
abundance of p27 was detected using a polyclonal antibody for p27 (1:100) and HRP
conjugated secondary antibody (1:500) and alkaline phosphatase conjugated secondary
antibody (goat-anti rabbit). The membrane was then washed thoroughly with PBST and
treated with enhanced chemiluminescence (ECL) or enhanced chemifluorescence (ECF).
The data show a marked decrease in cellular p27 in cells treated with 1 OOnM endothelin1. ET-1 appears to have mitogenic properties in BCEC by downregulating the expression
of p27. Stimulation of cell proliferation may be mediated by suppressing the expression
of p27, a cyclin dependent kinase inhibitor.
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CHAPTER 1

Introduction

The Cornea
The cornea is a transparent dome shaped window that covers the anterior of the
eye. It is a highly organized group of cells and proteins that is smooth and clear but
strong and durable. The cornea receives its nourishment from tears and aqueous humor
that fills the chamber behind it. The cornea must remain transparent to refract light
properly. To see well, all of the cornea must be free of any particles, which prevent light
from reaching retina (1). The corneal organ is comprised of five layers, each having a
distinct function. The outermost layer is the stratified epithelium which comprises
approximately ten percent of the tissue's thickness. Its main function is to block the
passage of microorganisms and nonliving particles into the eye. It also provides a smooth
surface for absorption and distribution of oxygen and cell nutrients to the rest of the
cornea. The epithelium also acts as a sensory tissue; it is filled with thousands of tiny
nerve endings that make the cornea extremely sensitive when rubbed or scratched. The
epithelium possesses a basement membrane which serves as foundation on which the
epithelial cells anchor and organize themselves. Lying below this membrane is a
transparent sheet of tissue known as Bowman's layer, which is composed of collagen
(strong layered protein fibers). If the Bowman's layer is injured, it can form a scar as it
heals, and this scarring can result in vision loss.
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Beneath the Bowman's layer is the stroma, which comprises about 90% of
cornea's thickness. It consists of water (about 78%) and collagen (about 16%); its main
function is to give the cornea strength, elasticity and form. Collagen's unique shape,
arrangement and spacing are essential in producing light-conducting transparency. Under
the stroma is Descemet's membrane, which is a thin but strong sheet of tissue that serves
as a protective barrier against infection and injuries. The Descemet's membrane is made
by the endothelial cells that lie below; these endothelial cells, collectively called an
endothelium, form the innermost layer of cornea.
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Corneal Endothelium
The corneal endothelium is a single layer of cells located at posterior of the
cornea. The chief function of the corneal endothelium is to maintain corneal transparency
(2). As fluids leak slowly from the aqueous humor into the stroma, the endothelium
pumps this excess fluid out of the stroma (1, 4). Without the pumping action, the stroma
would swell with water, and become hazy and eventually opaque. A healthy eye
maintains a perfect balance between the fluids moving in and out of the cornea. In the
early stages of corneal development, the endothelial cells actively divide to form the
endothelium (3). When these cells mature they establish the gap and tight junctions,
which results in the cessation of proliferation. The endothelial density decreases with age
(4), and this loss is further accelerated by disease (5). The capacity of the corneal
endothelium to regenerate is severely limited in man and other primates (3,4). Thus
corneal wound repair is achieved primarily by cell enlargement and by redistributing
existing cells (4). It is not clear why corneal endothelium exhibits limited capacity to
proliferate, but molecular events governing the cell cycle may play a role (4, 6). Recent
findings on the expression of cell cycle associated proteins in donor human corneas
suggest that human corneal endothelial have not exited the cell cycle but are arrested in
G-l phase, suggesting these cells could possess proliferative potential (6).
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The Cell Cycle
The cell cycle is a series of events in a eukaryotic cell between one cell division
and the next. It consists of four phases: the G1 phase, the S phase the G2 phase (together
these phases are called interphase) and the M phase. The M phase is composed of two
tightly coupled processes: Mitosis and cytokinesis. In mitosis the cell's chromosomes are
replicated and divided between the two daughter cells. In cytokinesis the cell cytoplasm
physically divides. Cells that have temporarily stopped dividing are said to be in a state of
quiescence (also called Go phase), while cells that have permanently stopped dividing due
to age or accumulated DNA damage are said to be senescent. The cell cycle coordinates
events needed for the growth of all eukaryotic cells. Events such as DNA replication (Sphase) and cell division (M-phase) occur in the right temporal sequence and proceed in
an orderly fashion (7). In addition, the cell cycle receives and integrates signals from
diverse growth regulatory pathways, ensuring that the cell grows only in the presence of
the appropriate signals and in the right environment (8). There are two key classes of
regulatory molecules that determine cell's progress through the cell cycle: cyclins and
cyclin dependent kinase.
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Important regulatory proteins in the cell cycle

In mammalian cell division, the progression through the first gap phase (Gl) of the
cell cycle and the initiation of DNA synthesis (S phase), of which are mitogen-dependent,
are cooperatively regulated by several classes of cyclins and cyclin dependent kinases
(CDKs) (8). Cyclins control the progression of cells through the phases of the cell cycle
by forming complexes with cyclin dependent kinases (CDKs). The CDKs are a family of
heterodimeric serine/threonine protein kinases, each consisting of a catalytic CDK
subunit and an activating cyclin subunit. In most eukaryotes, there are different CDKs
that control the different stages of the cell cycle. They coordinate the cell cycle by acting
as on and off switches (7). When a CDK is on, the cell cycle progresses through the stage
that particular CDK controls. When a CDK is off, cell cycle stops when it reaches the
stage controlled by that particular CDK (7, 8).
Regulation of cyclin-CDKs complexes occurs at multiple levels, including the
assembly of cyclin and CDK. Cyclins are the regulatory subunits of these complexes, and
the enzymatic activity of CDK is dependent on physical interaction with one of the cyclin
proteins. In addition, CDK activity can be negatively regulated by a group of proteins
collectively termed CDK inhibitors (CDKIs) (5). The CDKIs are a newly recognized
family of proteins (7) and are well characterized for their role as negative regulators of
the G-l phase of the cell cycle (9). CDKIs that govern these events have been assigned
to one of two families based on their structures and CDK targets. The first family
includes the INK4 proteins (inhibitors of CDK4). The inhibitors work by binding to
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CDK4 and CDK6 (8); they bind isolated CDK and prevent its association with the cyclin
(7).
The second family of inhibitors, CIP/KIP, inhibits a broad array of cyclin-CDK
complexes (8) hence they are designated as universal CDKI. They interact with various
CDK complexes, which eventually lead to inhibition of kinase activities of pre-activated
Gl, cyclin E-CDK2, and cyclin D-CDK4/6. The CIP/KIP family includes p21, p27 and
p57. Members of KIP proteins share a great deal of homology, e.g., p27 protein have a
42% amino acid homology with p57 at amino terminal domain. The amino terminal
domain mediates inhibition of CDK (10).
P27 was originally identified as an inhibitor of CDK complex that is induced by
antimitogenic signals (3, 25). Forced expression of p27 results in Gl-phase cell cycle
arrest (9). Normally the progression of cell cycle Gl/S requires p27 proteolysis, which is
initiated by the phosphorylation of p27 on threonine-187 (9, 10).
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The p27 cyclin dependent kinase inhibitor
P27 is a member of the universal cyclin dependent kinase inhibitor (CDKI) family
and its gene was cloned in 1994 (26). P27 expression is regulated by cell contact
inhibition and by specific growth factors such as transforming growth factor TGF-/3 (10).
P27 has several functions such as tumor suppression, regulation of drug resistance in
solid tumor, the promotion of apoptosis and cell differentiation.
The cycle through which a cell moves as it divides and replicates itself is tightly
regulated to control cell growth; cyclins and their partners, the cyclin dependent kinases
(CDKs), are instrumental in driving the cell cycle forward. Cyclin D/CDK4 complexes
function early in the cell cycle, while cyclin E/CDK2 complexes function later. P27 acts
as an inhibitor of CDK2 activity and is required early in the cell cycle for the assembly of
cyclin D1/CDK4 complexes. This suggests that p27 permits early progression but
suppresses later progression of the cell cycle (11).
P27 was first identified in cells treated with transforming growth factor (TGF-/3)
or by stimulation of contact inhibition; under these conditions it was found as an inactive
form bound to cyclin-E-CDK-2 (10,11). The protein was purified from a cyclin-E-CDK2
affinity column and characterized by its strong inhibitory activity toward cyclin-E CDK2. P27 can directly inhibit the enzymatic activity of CDK-cyclin complexes and
arrest cells in G1 (10). The association of p27 with CDK4- cyclin D or with CDK2-cyclin
E complexes prevents phosphorylation of CDK4 on Threonine-172 and CDK2 on
Threonine -160 via a CDK activated kinase (9, 10, 11). The level of p27 protein
expression is high in G0/G1 resting cells and declines as cell progresses towards the S-
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phase. Overexpression of p27 has been shown to inhibit entry into the S-phase in normal
and malignant cells (5).
Mutation in genes encoding the KIP/CIP inhibitors p21 and p27 are rare. In
mice, p27 behaves like a tumor suppressor. The loss of only one gene copy decreases the
levels of p27 and susceptibility to cancer. The increase in levels of p27 in quiescent cells
rapidly reduces after stimulation with mitogens (12, 13).

Endothelin
Endothelin (ET) is a potent vasoconstrictor/vasopressor peptide originally
characterized from the culture supernatant of porcine aortic endothelial cells and consists
of 21 amino acid residues with two sets of intrachain disulfide linkages (12, 13).
Sequence analysis of the cloned cDNAs for porcine and human endothelin precursors
showed that endothelin is produced in endothelial cells from a precursor of approximately
200 residues (preproendothelin) (13,14). A presumptive 39 residue (porcine) or 38
residues (human) is thought to be generated from preproendothelin. The amino acid
sequences of the mature porcine and human endothelin are identical. Since its discovery
in 1985 and its first detailed characterization in 1988, 3 ET isoforms have been described:
ET-1, ET-2 and ET-3 (13). The vasoconstrictor potency is highest with ET-1. All ET
isoforms are composed of 21 amino acids with two intrachain disulfide bridges. This 21residue (mature) endothelin is produced through unusual proteolytic processing of big
endothelin between Trp21 and Val22 residues. A variety of cells including, vascular
endothelial cells, heart, brain, spinal chord, pulmonary epithelial cells, glomerular
mesangial cells, renal epithelial cells, monocytes and macrophages synthesize ET. After
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biosynthesis, ET is released into the circulation or it diffuses towards the underlying
vascular smooth muscles cells. ET-1 production in glomerular mesangial cells is
stimulated by a variety of cytokines and growth factors, including IL-/3, TNF-a, TGF-/3,
PDFG and vasopressin. Inhibiting factors include nitric oxide, prostacyclin and atrial
natriuretic (14).
Endothelins exert their effects by binding to two distinct cell surface receptors,
ET-AR and ET-BR. These receptors are found on smooth muscle cells, myocytes and
fibroblasts. The binding to the receptor leads to various cellular outcomes i.e. efflux of
cellular calcium, release of intracellular stored calcium, and inhibition of Na/K ATPase
(12, 13). The ET-BR binds the three peptides isotypes with equal affinity; in contrast,
ETAR binds ET-1 with higher affinity than the other isoforms. Both receptors belong to
the G-protein coupled receptor (GPCR) system and mediate biological responses from a
variety of stimuli, including growth factors, vasoactive polypeptides, neurotransmitters,
hormones and phospholipids (12).
The physiological importance of the cleavage of big ET is indicated by the
increase in vasoconstrictor potency. However the half-life of the cleavage product is less
than a minute (12). It is rapidly removed from the circulation by the kidney, the lung and
vascular endothelial cells. In addition to the potent vasoconstrictor and vasopressor
actions, endothelin has been reported to produce a wide spectrum of biological effects
including contraction of airway and intestinal smooth muscles, release of eicosanoids and
/or endothelium derived relaxing factor from vascular beds, and inhibition of renin
release from the glomerulus. It can stimulate the proliferation of vascular smooth muscle
cells and fibroblasts. (4, 9, 13).
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Recently, investigations into the role of the endothelin in mitogenesis have
provided evidence of the importance of the ET-1 in cancer. Data suggest that ET-1
participates in a wide range of cancer relevant processes such as cell proliferation,
inhibition of apoptosis, matrix remodeling, bone deposition and metastases (12). ET-1
stimulates DNA synthesis and cell proliferation in various cells including vascular
smooth muscles, osteoblasts, gromerular mesangial cells, fibroblasts and melanocytes.
ET-1 is also a mitogen for different cell types including prostate, cervical and ovarian
cancer cells. In primary cultures and established ovarian carcinoma cell lines,
spontaneous growth was significantly inhibited in the presence of antagonists,
specifically the one which blocks ET-AR (15). The mitogenic activity of ET-1 can be
amplified by synergistic interactions with other growth factors including epidermal
growth factor (EGF), basic fibroblast growth factor (bFGF), platelet derived growth
factor (PDGF), transforming growth factor and interleukin-6 (IL-6) (16).
A specific ETA receptor, BQ123 is a well-characterized synthetic pentapeptide
with high selectivity for the ETA receptor and thus high potency for ETA receptor
antagonism (17).
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Hypothesis and Purpose of Research
A long term potential outcome of this line of investigation is to develop a
potential therapy to increase cell proliferation in corneal endothelial cells. The proposed
approach is to reduce the expression of p27 by transiently stimulating corneal endothelial
cells with endothelin-1 (ET-1).We also investigated whether the specific ET-1 receptor
antagonist, BQ123, may inhibit the suppression of p27.
Primary cell culture of bovine corneal endothelial cells (BCECs), a widely
used model of the corneal endothelium, will be used to determine whether the expression
of p27 can be altered (reduced) in the presence of ET-1. We hypothesize that upon
treatment with ET-1, the expression of p27 will decrease. If the expression of p27 is
decreased, we expect that the cell cycle arrest will not occur, and the cells will continue
to proliferate. This (decrease of p27), will be of potential therapeutic interest (at the
moment the only way to correct damaged cornea is by transplantation, which is costly
and has potential side effects). An agent that transiently inhibits p27 expression may be
useful for treating an injured or diseased cornea by allowing replication of endothelial
cells, and hence promoting healing of this tissue.
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CHAPTER 2
Materials and Methods

Isolation and culture of bovine corneal endothelial cells (BCECs)

Cow eyes were obtained from Kirby and Poe abattoir (Alvaton, Kentucky). The
globe was placed cornea side up in a shallow dish lined with paper towel. A 2X antibiotic
solution (from lOOx stock penicillin/streptomycin/ nystatin) was dropped on the globes
and soaked for 30 minutes at room temperature after being covered with sterile gauze.
The cornea was dissected with a l-2mm scleral rim and transferred endothelium side up
to the eyecup and rinsed with dispase dissolved in Earle's Balanced Salt Solution (EBSS)
(Invitrogen, CA). The cornea was incubated with dispase-EBSS at 37°C for 90 minutes.
The endothelium was then gently scraped using spatula with a tapered silicon rubber tip.
Cells were aspirated with a sterile Pasteur pipette and transferred to a sterile 15ml
centrifuge tube containing 5ml of basal medium (Dulbecco's Eagle's Medium -DMEM)
(Invitrogen, Carlsbad, CA) supplemented with 10% calf serum (Hyclone, Logan, UT)
and 100/xl gentamycin, IOOJU.1 fungizone (antibiotic-antimycotic) and pelleted by
centrifugation at 600xg for 2 minutes. The supernatant was decanted and the cell pellet
resuspended with 5ml of basal media. Cells from two eyes were then transferred to a
25cm 2 culture flask (T25). The cultured cells were maintained in basal media in a 5%
CO2, 37°C incubator. For subculture, cells were treated with trypsin (0.05% in calcium +
magnesium with EBSS containing 0.6mM EDTA) and were pelletted by centrifugation at
600xg for two minutes. The cell pellet was then resuspended in appropriate volume of
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basal media and transferred to flasks. After the cells reached approximately 99%
confluence, they were deprived of serum for twenty-four hours, some were treated with
lOOnM ET-1, ljiM BQI23, combined (BQ123 + ET-1) and others left untreated i.e. they
were not treated with either ET-1 nor BQI23 .

Cell lysis and isolation of proteins

BCECs were washed with cold EBSS, gently scraped from T25 flasks, and
washed with ice cold phosphate buffered solution (4.38g NaCl, 1.38g NaP04 monobasic
in 1 Liter) cells were then lysed with lysis buffer (20mM Hepes, 10% glycerol, 0.1 mM
dithiothreitol (DTT), 1% tritox-lOOx and protease inhibitor cocktail) on ice for 30
minutes with occasional rocking. The cell lysate was collected and sonicated on ice 2x
for 10s, and the contents were aliquoted into 1ml tubes, and stored in a -20°C freezer for
further analysis. The protein content was assessed by the Peterson modification of the
Lowry protein assay using bovine serum albumin as a standard (18).

SDS-polyacrylamide

gel electrophoresis (SDS-PAGE) and immunoblot

analysis

Cell lysates were solubilized in 5x solubilizing buffer (0.145M Tris, 0.025%
bromophenol blue, 5% SDS, 25% glycerol) at a ratio of 1:4, and subjected to 90 °C for
five minutes, followed by addition of beta-mercaptoethanol (BME) to a final
concentration of 5%. Samples containing 20-40/il BCECs lysate were then analyzed by
SDS-PAGE (Bio-Rad Laboratories, Hercules, CA). The 4-12% precast gradient gel was
run at a constant voltage of 50V for three hours. The conditions of electrophoresis were
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as described by Laemmli (29). Half of the gel was placed in coomasie blue stain to check
for protein migration. Before transfer, the unit was assembled as follows: two sheets of
whatman #1 paper and one sheet polyvinylidenedifluoride membrane (PVDF) were cut to
8cm x 5cm. The PVDF membrane was carefully wetted in methanol (to remove
hydrophobicity); the rest of the assembly unit then wetted with transfer buffer (1% SDS,
20% methanol in lx running buffer (0.3g tris base + 1,44g glycine brought up to 1L with
DI water) for at least 5 minutes. A blot sandwich was built on the sponge in the following
order: Whatman paper, gel, PVDF, Whatman paper, each piece was layered on the
sandwich. The sandwich was placed in such a way that proteins will migrate out of the
gel and onto PVDF membrane. (PVDF side of the sandwich was towards the positive
electrode). The separated proteins were then transferred from the gel to the PVDF
membrane at a constant voltage of 30V overnight. The tank transfer blotting method was
used to transfer proteins to the membrane.

Immunodetection

of proteins

After overnight blotting, the PVDF membrane was removed from the transblot
apparatus and placed in a flat dish and blocked with 5% non-fat dry milk (i.e. 25g non fat
dry milk in 500ml lx PBS) for one hour at room temperature. The primary antibody
rabbit anti-human p27 polyclonal antibody, (Zymed Laboratories, San Francisco, CA)
was diluted at 1:100. In this case 6/d of antibody was added to 600[il of medium (PBS +
0.1% Tween-20, i.e. PBS-T). The primary antibody was then added and the membrane
was incubated for lhr, at 37°C. 30ml of PBS-T was then added to the dish while shaking,
at 37°C for 5min, PBS-T was decanted and the process repeated until the sheet was
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washed 6 times. To test for non specific binding, immunoblots were performed with the
primary antibody omitted.

The membrane was then incubated with secondary antibody. The experiment was
performed independently using two sets of antibodies, goat anti-rabbit polyclonal
antibody diluted at 1:500 conjugated to horseradish peroxidase (HRP) and goat antirabbit polyclonal antibody (diluted at 1:200) conjugated to alkaline phosphatase (AP)
(Southern Biotech, Birmingham, Alabama) was used. Secondary antibodies were added
to the membrane in dish and incubated for lhr at room temperature with gentle shaking.
The antibody was decanted and 30ml of PBS-T then added to the dish with gently
shaking at 37°C for 5min. The PBS-T was decanted and the process repeated until the
sheet has been washed six times at 5 minute intervals. The membrane was then treated
with the enhanced chemiluminescence (ECL) reagent (Amersham Pharmacia Biotech,
Buckinghamshire UK). The ECL-treated membrane was exposed to a digital imager
(Storm). In the second experiment the membrane was treated with enhanced
chemi fluorescence (ECF) (Amersham Pharmacia Biotech, Buckinghamshire UK) and
exposed to digital imager.
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Results
Protein

concentration

While the protein concentration in the lysate of ET-1 treated cells was highest, it
was not statistically significant, i.e., protein concentrations of the cell lysate were
2.90jag/(al for untreated BCEC, 3.10 (ig/(il in lOOnM endothelin-1 treated, 2.99pg/|al in
BQ123 + endothelin-1 and 2.97 ng/^1 in BQ123 treated BCEC.
Quiescent BCECs express p27
Expression of p27 was determined by western blot analysis. When BCEC cells
reached 90% to 99% confluence, they were placed in serum free medium for 24 hours
and proteins harvested. 15 ug of total proteins were loaded on the second and lane while
30|ag loaded on the 3rd lane the rest of the lanes were left (unloaded). A band below 28.8
molecular weight marker consistent with p27 was obtained. As predicted, the band at
approximately 27kDa was thicker in lane 3 (figure 1).
Endothelin-1 downregulates p27
To test for the expression of p27 in BCECs, confluent cells were placed in serum
free medium for 24 hours. Some were left as control, (untreated) and the rest treated with
lOOnM Endothelin-1 for a further 24 hours. 30jug of each sample was subjected to SDSPAGE on a 4-12%) gel and immunoblot analysis performed. The endothelin-1 treated
cells showed a marked decrease in p27 expression (figure 2).
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Non specific binding
To test for possible non specific binding, two membranes from two experiments
were compared. When cells reached 90% to 99% confluence, they were placed in serum
free medium for 24 hours (left untreated), and sample subjected to SDS-PAGE on a 412% gel and immunoblot analysis performed in the absence of primary antibody. Non
specific binding to a protein between 75kDa and 48 kDa markers was observed in two
experiments (figure 3). The band corresponding to p27 was absent. Although this does
not prove the identity of the band as p27, it does show the observed band at
approximately 27 kDa (figure 1) was not due to non-specific binding (presence of the
secondary antibody) (figure 3). A positive control utilizing purified p27 protein was not
performed.

The effect of ET-1 Receptor antagonist (BQ123) is unclear
To elucidate the role of Endothelin-1 receptor antagonist (BQ123), confluent cells
were deprived of serum for twenty four hours (untreated) and then treated with lOOnM
ET-1, or BQ123, or both combined (BQ123 +ET-1). 30(ag of each sample was subjected
to SDS-PAGE on 4-12% gradient gel and immunoblot analysis performed. The
expression of p27 seemed to be downregulated by BQ123, however a poor transfer of
proteins to the membrane was observed (Figure 4). The experiment was repeated three
times and Statistical analysis was performed with repeated-measures ANOVA, P=0.0026
and post test Student-Newman-Keuls (SNK) (Figure 5).
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Quiescent B C E C s express p27
A
1

2

15jj.g protein

B
3

4

5

1

2

3

4

5

30|ig protein

Figure 1
Expression of P27 (determined by western blot). When BCEC cells reached 90% to 99% confluence,
they were placed in serum free medium for 24 hours and proteins harvested.
A: 15 (ig of total proteins loaded on the second lane while 30|ig loaded on the 3rd lane. The third lane has a
thicker band. The left arrow shows 28.8 molecular weight markers
B: Western blot analysis in the absence of primary antibody. There was absent of any band (except the
molecular weight standards) when western blot analysis was performed in the absence of primary antibody.
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Endothelin-1 treated and untreated BCEC culture

t

Unknown protein

^m jpMMB

28.8MW

*

Untreated

p27

Endothelin-1 treated

Figure 2
Effect of endothelin-1, on the expression of p27, when cells reached 90% to 99% confluence, they
were placed in serum free medium for 24 hours. Some were left as control, (untreated) and the rest treated
with lOOnM Endothelin-1 for a further 24 hours. 30|ig of each sample was subjected to SDS-PAGE on a 412% gel and immunoblot analysis performed.

26

Non specific binding
B
1

No p27 bands

2

3

4

5

No p27 bands

Figure 3

To test for non specific binding the membranes were compared from two experiments
A: When cells reached 90% to 99% confluence, they were placed in serum free medium for 24 hours (left
untreated), and sample subjected to SDS-PAGE on a 4-12% gel and immunoblot analysis performed in the
absence of primary antibody.
Lane 1: 30ng, lane 2: 15|ig, lane 3: 30|ig, lane 4: 15|ig
B: When cells reached 90% to 99% confluence, they were placed in serum free medium for 24 hours (left
untreated), and sample subjected to SDS-PAGE on a 4-12% gel and immunoblot analysis performed in the
absence of primary antibody.
Lane 2: 15fj.g, lane3: 30|ig, lane 4: 0|ig protein, lane 5: 0|ug protein
Right arrow: location of non specific binding (band).
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Endothelin treated and receptor antagonist treated BCEC proteins

1

2

ET-I

3

4

Untreated

BQ123E

5

BQ123

Figure 4
Expression o f p 2 7 in BCEC treated with ET-1, BQ123+ET-1 and 1 jaM BQI23. When cells reached
approximately 99% confluence, they were deprived of serum for twenty-four hours (untreated) and then
treated with lOOnM ET-I, luM BQI23, both combined (BQ123+ET-1). 30 fig of each sample was subjected
to SDS-PAGE on 4-12% gradient gel under reducing conditions, and immunoblot analysis performed.
Lane2: cells treated with ET-1; lane3: control-untreated cells; Lane 4: cells simultaneously treated with
ET-1 and BQ123; Lane 5: cells treated with BQ123. The left arrow represent 28.8 MW marker, while the
right arrow shows unknown protein (a non specific binding between 75MW and 48 MW markers).
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Figure 5
Histograms represent relative levels of p27 determined by densitometry analysis of bands from
western blots.

All the immunoblot results were expressed as percentage relative to density of p27 bands (The
volume in the spot as a percentage of the total volume*. The total volume equals the sum of the volumes of
all the objects included in one quantitation) of all objects estimated using image analyzer. Histograms
represent relative levels of p27 determined by densitometric analysis of bands from western blots.
Statistical analysis was performed with repeated-measures ANOVA, P=0.0026 and post test StudentNewman-Keuls (SNK) Bars: Control; mean + SD of data from three experiments, p<0.001 compared to
BQ123, ET-1 and BQ123+ET-1. The expression o f p 2 7 in BQ123 treated cells was not clear because
proteins transfer efficiency to the membrane was low.
T h e integrated intensity of all the pixels in the spot, excluding the background. To calculate volume,
imageQuant subtracts the background value from the intensity of each pixel in the object, and then adds all
the values.
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CHAPTER 3
Discussion
It has been known that the ability for regeneration of corneal endothelium after
injury, age or other stresses is limited in humans because this tissue is thought to be
nonreplicating (19). However Joyce et al (6) have shown that corneal endothelial cells
cease to move out G1 phase of the cell cycle, which means they have proliferative
potential. This investigation explored ET-l's role as a mitogenic factor in corneal
endothelial cells and whether mitogenic activity is mediated through p27, a cyclin
dependent kinase inhibitor. Previously it was shown in our lab by indirect
immunofluoresce microscopy that p27 is present in bovine corneal endothelial cells
(BCEC). Our observation by immunoblot analysis (Figure 1), though not clear, seems to
suggest that p27 expression in BCEC was downregulated when the cells were treated
with lOOnM endothelin-1.
In this study, the role of ET-1 in the expression of p27 was investigated. The
preliminary results presented here could suggest a novel mechanism whereby the
expression of p27 was downregulated by ET-1. These effects were specific to
Endothelin-1 treated cells as they were not observed in untreated cells (Figure 2). Though
the action of ET-1 involves activation of signal transduction pathways, the specific action
and/ or mechanism of ET-1 on p27 is unknown. However, the results suggest this
mechanism might be due to the increased degradation of p27 in the cytoplasmic
compartment (15). Earlier studies suggested that p27 degradation in mammals is
mediated by both the ubiquitin proteosome pathway (21) and by ubiquitin-independent
proteolytic cleavage (19). The ubiquitin pathway is emerging as a major mechanism that
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regulates the selective and time control elimination of key short-lived proteins such as
CKIs, this mechanism is achieved by phosphorylation of the target protein. In the case of
p27, phosphorylation occurs on threonine-187 (19). In breast cancer cells, p27
phosphorylation occurred almost exclusively in the cytoplasmic compartment, it probably
reflects impaired nuclear import of p27 (19, 20). Taking this mechanism into account, the
findings of this investigation raises the possibility that the effect of ET-1 binding to ETA
receptor on the surface of B C E C may result in additional mechanisms which might have
an impact on p27 protein. For example, the cytoplasmic phosphorylated p27 has been
shown to bind to cytoplasmic proteins such as 14-3-3 protein, which prevents p27 nuclear
export, consequently, there is no binding to cyclin D and eventually, the cell proliferates
(20).

Elucidating the function of ET-1 is crucial for cancer research; low level of P27
protein due to the administration of ET-1 possibly stimulates cell division (cells enter Sphase), which might coincide with the downregulation of p27 (figure 5). However, in this
experiment the level of protein was not significantly different in ET-1 treated and
untreated cells. Yang et al (22) could demonstrate that ET-1 alone was not able to
increase smooth muscle cell proliferation. The ineffectiveness of ET-1 to stimulate
smooth muscle cell proliferation was further confirmed by the result that ET-1 was not
able to activate cyclin dependent kinase-2. Furthermore the CDK inhibitor, p27, was
downregulated and the retinoblastoma protein, pRb, was not hyperphosphorylated, this
being crucial for cell cycle progression (23). The indication is that the binding of ET-1 to
the ET a receptor is responsible for potentiating its (ET-1) effects (30). However the
relationship between ET-1 and the transforming growth factor TGF-J32 is well
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documented. TGF-p2 which is present in the aqueous humor of the anterior chamber has
been proposed to suppress mitotic activity of cells (19, 22). TGF-P2 exerts its
antimitogenic effect through p27, and can inhibit both cyclin-D-CDK4 and cyclin-ECDK2. Expression and kinase activity of CDK2 enhanced by ET-1 increased
significantly the cross sectional area and number of smooth muscle cell (19).
It is necessary to point out however that in addition to the downregulation of p27
by ET-1, our results suggest that BQ123 downregulates p27 (figure 5). This
downregulation is intriguing because BQ123 is a receptor antagonist; there are several
possibilities that can explain the effect of BQ123. First, BQ123 may contribute directly to
the downregulation of p27 (figure 4) independent of receptor binding. Secondly, BQ123
might prevent p27 localization to the nucleus, which is important for cytoplasmic
degradation of p27. This needs further investigation because our results showed poor
transfer of proteins (in BQ123 section) from the gel to the membrane.
Considering the importance of the different biological functions of p27: regulation
of cell growth, contact inhibition and apoptosis among others, the combined use of both
ET-1 and BQ123 (figure 5) might be a useful tool to better characterize their roles in cell
proliferation. Recent studies have shown that the expression levels of p27 are decreased
in proliferating cells such as aggressive breast cancer cells (7). Taking into consideration
the findings of this study, it could be possible that ET-1 stimulates uncontrolled
proliferation of cells which might eventually commit the cell to a tumor. In contrast
BQ123 affects the overall physiological activity of the cell which indirectly affects the
regulation of p27. ET-1 is crucial in stimulating growth in various cancers. Therefore ET1 activity could account in generating tumor cells. Venuti et al (15) have previously
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suggested a role for ET-1 in the regulation and promotion of cervical tumor growth. This
growth promotion may result from the ability of ET-1 to act alone or with various growth
factors such as EGF.
Conclusion
In conclusion, this study indicates that ET-1 may potentially play a role in
promoting the regeneration of corneal endothelium after the cells are destroyed due to
injury, disease or other stresses. This investigation suggests that the CDK inhibitor, p27,
is functionally down regulated by the mitogen ET-1. However, the effect of its receptor
antagonist BQ123 was unclear. ET-1 is important in BCEC cells moving out of Gl, and
may be critical in the continuous proliferation of BCEC. Indeed, the pattern of p27
expression suggests there could be other mechanisms, which regulate proliferating bovine
corneal endothelial cells where ET-l's role needs to be investigated further.
Further studies
The effect of Endothelin-1, BQ123 and BQ123 + ET-1 on the expression of p27
in a cell may be a sign of mitogenic effect when they bind independently to and/or
compete for ETA receptor. Though it is not clear how BQ123 could affect cell
proliferation, our results indicate that BCEC responded to ET-1 treatment. Hence further
investigation is required to determine whether the change in the expression of p27 in the
presence of ET-1 and BQ123 is related to cell proliferation.
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